Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ooking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes availabl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:3/4/2015)... , March 4, 2015  Bayer HealthCare ... Administration (FDA) has accepted the company,s Biologics License ... VIII compound.  Bayer is seeking FDA approval of ... the treatment of hemophilia A in children and ... continually bringing new therapies to hemophilia A patients ...
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... March 4, 2015 Sanomedics , ... a medical technology company that focuses on providing ... that the Company,s subsidiary, Thermomedics, Inc. , has ... and Government Sales. LeBel will be reporting to ... Sales, and will be responsible for supporting assigned ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 2Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 3
... , SAN MATEO, Calif., July 24 ... today the preliminary results of a short-term clinical study ... (PHN) following pretreatment with an FDA-approved topical anesthetic. As ... the U.S. Food and Drug Administration (FDA) requested the ...
... , , WISCONSIN ... of Wisconsin Cancer Center Riverview became the first medical facility ... of skin cancer. Located within Riverview Hospital, Wisconsin Rapids, the ... cancer patients with the FDA-cleared Axxent(R) Electronic Brachytherapy System from ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:3/5/2015)... Developers and plugin specialists of Final ... transition pack entitled TranSlice Wipe for FCPX. , “TranSlice ... ease while maintaining a professional look,” Said Christina Austin, ... time saver with transitions our users will love.” , ... screen transitions with a new style. TranSlice Wipe allows ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 New fiber fix ... store TheHardwareCity.com is a one of a kind product, manufactured ... being received positively in its short time in the market ... fragments of broken fiber glass objects which cannot be done ... City commented, “We really are excited about our new product ...
(Date:3/5/2015)... Southlake, TX (PRWEB) March 05, 2015 ... an in-office, non-surgical treatment for OB-GYNs and Urogynecologists. ... system, used for non-surgical dermatological application in aesthetics ... pleased to have a non-invasive, in-office procedure, and ... for women who want results without surgery. ThermiVa ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The Shaolin ... for Health and Wellness at Atlanta Shaolin Institute along ... 4350 Peachtree Industrial BLVD, Suite 500A, city of Peachtree ... Chan Foundation), which is a non-profit organization that promotes ... philosophy and medicine. , The seminar was well ...
(Date:3/4/2015)... London, UK (PRWEB) March 05, 2015 ... the clinical therapeutics landscape over the past decade. ... nanoscale carriers for drug delivery in the form ... of delivering manifold drugs with more safety and ... the nanoparticles could perhaps rely greatly upon the ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2Health News:TheHardwareCity.com Launches New Fiber Fix Heat Wrap For High Temperature Applications 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 3Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3
... all set to shock parents of modest means and desirous ... in Karnataka where the fee of private medical colleges is ... the Fee Fixation Committee headed by Justice H Rangavittalachar, which ... fuming.,The college which quoted the highest annual fee of Rs ...
... The health of UK's sex workers will be adversely affected ... seeks to improve the quality of life of the people ... commercial sex exploitation, and also challenge the opinion that street ... degree of policing in red light areas, which may also ...
... of Veterinary Medicine has developed cancer vaccine for the ... worked in collaboration with the oncologist from Arizona, California, ... very efficient in preventing the death of the animal, ... treatment. Ilene Kurzman, a researcher in the veterinary ...
... Prince of Wales said that there is an increase in ... to balance their lifestyle and exercise regularly. ,He ... are// following the close behind the United States in the ... infrastructure of the city discourages pedestrians and physical activity. ...
... the University of Manchester have evolved a method to diagnose ... detect chemical warfare agents. Dr Paul Thomas led a team ... explosives at the airports. // ,The ... is now being used by researchers to detect "unhealthy" molecules ...
... and his colleagues have reported in the Cochrane Database ... genital tract reduces// the surgical procedure such as Episiotomy ... surgical procedure done in the perineum in the area ... involved during birthing process to expand the opening of ...
Cached Medicine News:Health News:Sensor Can Detect "Unhealthy" Molecules In Breath 2
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
... Simple, compact, and easy to use, the ... technology to every OR. The business model ... hospitals and surgeons with the most flexible ... facilities. ,The z-boxTM is designed to run ...
NOW Legionella is an immunochromatographic membrane assay to detect Legionella pneumophila serogroup 1 soluble antigen in human urine....
Medicine Products: